language
Language
Englishchevron_right
attach_money
Currency
$USDchevron_right
dark_mode
Dark Mode
policy
Privacy Policy
gavel
Terms of Service
WATWAT

$387.37

+1.23
arrow_drop_up0.32%
Current Market·update12 Nov 2025 21:00

$386.37

-1.00
arrow_drop_down0.26%
Pre-market·update13 Nov 2025 13:46
Day's Range
382.91-391.79
52-week Range
275.05-423.56

Chart

Loading chart...

Performance

Key Stats

Next Earnings Date2025-11-04
Next Earnings TimeBefore Market Open
Volume410.34K
Average Volume 30d672.72K

AI WAT Summary

Powered by LiveAI
💰
25.1
Valuation (P/E Ratio)
Reasonable Valuation - Trading below historical average.
📈
-0.098
EPS Growth (YoY)
EPS Decline - Recent performance shows a slight decrease.
Show More 🔒

AI Scoreboard

Powered by LiveAI
🔒

Overall Analysis

Buy
78

Waters Corporation (WAT) presents a balanced investment profile. It exhibits strong fundamental health with consistent profitability and a solid balance sheet, supported by its leadership in analytical workflows. Thematic tailwinds in healthcare and life sciences are positive. However, recent performance indicates a downward trend, and current technical indicators suggest a degree of caution is warranted for short-term trading. A long-term perspective with a focus on its market position and innovation is recommended.

Strong

Thematic

85

Waters Corporation is well-positioned to benefit from key secular growth trends in healthcare, diagnostics, and scientific research. Its advanced analytical workflow solutions are critical for drug discovery, clinical testing, and ensuring quality and safety across various industries.

Strong

Fundamental

80

Waters Corporation demonstrates strong financial health characterized by healthy profitability, a strong balance sheet, and consistent earnings generation, although recent performance metrics show some softening.

Neutral

Technical

63

Waters Corporation's stock is currently trading below its key moving averages, indicating a bearish short-term trend. While some oscillators suggest potential for a bounce, the overall technical picture points to a period of consolidation or further downside pressure in the immediate term.

FactorScore
Healthcare & Life Sciences Demand90
Technological Advancements (e.g., AI in R&D)80
Quality Control & Safety Standards85
Emerging Markets Growth85
Competition & Disruption70
FactorScore
Valuation65
Profitability90
Growth40
Balance Sheet Health75
Cash Flow85
Earnings Quality70
FactorScore
Trend Analysis30
Momentum40
Volume Confirmation70
Support & Resistance60
Short-Term Oscillators50

AI Investing Checklist

Powered by LiveAI
thumb_up

Bullish Points (7)

Earnings Performance chevron_right

Consistent EPS Beats

Waters Corporation (WAT) has a history of beating earnings per share (EPS) estimates, with positive surprises in the last 8 reported quarters, averaging a surprise of 4.21%.

Valuation chevron_right

Reasonable P/E Ratio

The trailing P/E ratio of 27.11 is below the technology sector average of 30.5, suggesting the stock may be attractively valued relative to its peers.

Show More 🔒
thumb_down

Bearish Points (7)

Performance chevron_right

Recent Underperformance

The stock has experienced a significant decline over the past month (-15.9%) and 6 months (-27.98%), suggesting potential headwinds or a loss of investor confidence.

Valuation chevron_right

High Price-to-Sales Ratio

The trailing Price-to-Sales (P/S) ratio of 7.8 is significantly higher than the industry average of 5.0, indicating that the stock might be overvalued relative to its sales.

Show More 🔒

Calendar

November 1996

26

Ex-Dividend Date

August 2025

4

Next Earnings Date

EPS Est.
Revenue Est.

H: $3.10

A: $2.95

L: $2.89

H: 770.00M

A: 748.32M

L: 740.00M

Profile

Websitewaters.com
Employees (FY)7.6K
ISIN-
FIGI-

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Seasonals

2025
2024
2023
2022
2021

Price Target

373.24 USD

The 39 analysts offering 1 year price forecasts for WAT have a max estimate of 465.00 and a min estimate of 330.00.

Debt Level and Coverage

Debt
Free cash flow
Cash & equivalents

Financial Position Analysis

Assets
Liabilities

Ownership

Free Float shares
59.4M (99.80%)
Closely held shares
120K (0.20%)
59.5M
Free Float shares
59.4M (99.80%)
Closely held shares
120K (0.20%)

Capital Structure

Market cap
17.76B
Debt
1.7B
Minority interest
0.00
Cash & equivalents
324.42M
Enterprise value
19.14B

Valuation - Summary

Market Cap
17.8B
Net income
514M(2.90%)
Revenue
2.27B(12.81%)
17.8B
Market Cap
17.8B
Net income
514M(2.90%)
Revenue
2.27B(12.81%)
Price to earning ratio (P/E)34.50x
Price to sales ratio (P/S)7.80x

Valuation - Ratios

P/E
P/S

Revenue to Profit Conversion

Revenue
2.96B
COGS
1.2B
Gross Profit
1.76B
OpEx
920.26M
Operating Income
837.92M
Other & Taxes
200.09M
Net Income
637.83M

Balance Sheet

Total assets
Total liabilities
Liabilities to assets %

Income Statement

Revenue
Net Income
Net Margin

Cash Flow

Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Show More 🔒